David McCall

2.1k total citations
73 papers, 1.1k citations indexed

About

David McCall is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Hematology. According to data from OpenAlex, David McCall has authored 73 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Public Health, Environmental and Occupational Health, 18 papers in Molecular Biology and 15 papers in Hematology. Recurrent topics in David McCall's work include Acute Lymphoblastic Leukemia research (18 papers), Acute Myeloid Leukemia Research (10 papers) and CAR-T cell therapy research (9 papers). David McCall is often cited by papers focused on Acute Lymphoblastic Leukemia research (18 papers), Acute Myeloid Leukemia Research (10 papers) and CAR-T cell therapy research (9 papers). David McCall collaborates with scholars based in United States, United Kingdom and Spain. David McCall's co-authors include J. F. Lamb, Ann M. L. Cavallo, Irwin B. Hanenson, Noble O. Fowler, John C. Holmes, Alan Katz, Branko Cuglievan, Kristi K. Ryan, Tobey J. MacDonald and David H. Munn and has published in prestigious journals such as Circulation, Blood and The Journal of Immunology.

In The Last Decade

David McCall

62 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David McCall United States 17 417 294 120 96 90 73 1.1k
G N Burrow United States 25 408 1.0× 36 0.1× 84 0.7× 86 0.9× 44 0.5× 61 1.6k
Albert Y. Wu United States 21 620 1.5× 69 0.2× 145 1.2× 128 1.3× 129 1.4× 84 1.5k
Martina Weber Germany 19 388 0.9× 298 1.0× 133 1.1× 182 1.9× 73 0.8× 32 1.5k
Hiroaki Tanaka Japan 24 298 0.7× 183 0.6× 184 1.5× 121 1.3× 52 0.6× 110 1.7k
Carl Christensen United States 19 285 0.7× 177 0.6× 99 0.8× 54 0.6× 86 1.0× 58 1.0k
Jinsheng Yang China 17 614 1.5× 150 0.5× 154 1.3× 36 0.4× 135 1.5× 46 1.3k
Yanli Wang China 22 353 0.8× 168 0.6× 98 0.8× 37 0.4× 60 0.7× 115 1.4k
Stanley Cohan United States 21 314 0.8× 102 0.3× 243 2.0× 79 0.8× 88 1.0× 94 1.6k
Amina Barhdadi Canada 15 402 1.0× 293 1.0× 242 2.0× 99 1.0× 34 0.4× 33 1.3k
Jia‐Shu Chen United States 18 223 0.5× 36 0.1× 70 0.6× 83 0.9× 53 0.6× 72 840

Countries citing papers authored by David McCall

Since Specialization
Citations

This map shows the geographic impact of David McCall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David McCall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David McCall more than expected).

Fields of papers citing papers by David McCall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David McCall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David McCall. The network helps show where David McCall may publish in the future.

Co-authorship network of co-authors of David McCall

This figure shows the co-authorship network connecting the top 25 collaborators of David McCall. A scholar is included among the top collaborators of David McCall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David McCall. David McCall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Corrigan, Kelsey L., Amy M. Berkman, Jillian R. Gunther, et al.. (2025). Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma. Cancer Epidemiology Biomarkers & Prevention. 34(9). 1483–1491.
2.
Berkman, Amy M., Clark R. Andersen, Nicholas J. Short, et al.. (2025). Risk of early death after acute leukemia diagnosis among adolescents and young adults. JNCI Cancer Spectrum. 9(4).
3.
4.
McCall, David, César Núnêz, Michael Roth, et al.. (2025). Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia. Blood Advances. 9(8). 1988–1990. 1 indexed citations
5.
6.
Li, Amanda M., Catherine Aftandilian, Susan I. Colace, et al.. (2024). A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 4204–4204.
7.
McCall, David, Ramya Ramakrishnan, César Núnêz, et al.. (2024). Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience. Cancers. 16(22). 3886–3886. 1 indexed citations
8.
McCall, David, César Núnêz, Michael Roth, et al.. (2024). Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia. Cancers. 16(5). 858–858. 3 indexed citations
9.
Short, Nicholas J., Elias Jabbour, Shilpa Paul, et al.. (2023). Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 24(4). e168–e173. 11 indexed citations
10.
11.
12.
Berkman, Amy M., Clark R. Andersen, Branko Cuglievan, et al.. (2022). Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiology Biomarkers & Prevention. 31(6). 1176–1184. 11 indexed citations
13.
McCall, David, Michael Roth, Kris M. Mahadeo, et al.. (2021). Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Advances. 5(23). 5215–5219. 6 indexed citations
14.
Lamhamedi-Cherradi, Salah-Eddine, Dhruva K. Mishra, David McCall, et al.. (2021). Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Therapy. 28(12). 1325–1338. 25 indexed citations
15.
McCall, David, Sajad Khazal, Michael Roth, et al.. (2021). Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers. 14(1). 150–150. 41 indexed citations
16.
Ragoonanan, Dristhi, César Núnêz, Michael Roth, et al.. (2021). DNMT3A Mutations Should be Considered in the Risk Stratification for Pediatric and Adolescent and Young Adult Patients with Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1308–1308.
17.
Ragoonanan, Dristhi, David McCall, Basirat Shoberu, et al.. (2020). Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. Frontiers in Oncology. 10. 1227–1227. 2 indexed citations
18.
Menegaz, Brian A., Salah-Eddine Lamhamedi-Cherradi, David McCall, et al.. (2019). Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomaterialia. 100. 38–51. 38 indexed citations
19.
McCall, David. (1978). Responses of cultured heart cells to procainamide and lignocaine. Cardiovascular Research. 12(9). 529–536. 2 indexed citations
20.
McCall, David. (1973). Effects of low concentrations of ouabain on cation exchange in cultured cells. The American Journal of Cardiology. 31(1). 145–145. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G N Burrow Breakdown of academic impact, for papers by Albert Y. Wu Breakdown of academic impact, for papers by Martina Weber Breakdown of academic impact, for papers by Hiroaki Tanaka Breakdown of academic impact, for papers by Carl Christensen Breakdown of academic impact, for papers by Jinsheng Yang Breakdown of academic impact, for papers by Yanli Wang Breakdown of academic impact, for papers by Stanley Cohan Breakdown of academic impact, for papers by Amina Barhdadi Breakdown of academic impact, for papers by Jia‐Shu Chen
Rankless by CCL
2026